<DOC>
<DOCNO>EP-0649431</DOCNO> 
<TEXT>
<INVENTION-TITLE>
17-AMINO SUBSTITUTED 4-AZASTEROID 5-ALPHA-REDUCTASE INHIBITORS
</INVENTION-TITLE>
<CLASSIFICATIONS>C07J3100	C07J4100	C07J1700	A61Q1900	A61Q500	A61Q700	A61K3158	C07J3100	C07J4100	C07J4300	C07J1700	A61Q700	A61K3158	C07J4300	A61Q500	A61K863	A61K830	C07J7300	C07J7300	A61Q1900	A61K800	A61K800	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07J	C07J	C07J	A61Q	A61Q	A61Q	A61K	C07J	C07J	C07J	C07J	A61Q	A61K	C07J	A61Q	A61K	A61K	C07J	C07J	A61Q	A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07J31	C07J41	C07J17	A61Q19	A61Q5	A61Q7	A61K31	C07J31	C07J41	C07J43	C07J17	A61Q7	A61K31	C07J43	A61Q5	A61K8	A61K8	C07J73	C07J73	A61Q19	A61K8	A61K8	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Novel amino substituted 4-azasteroid 5 alpha -reductase inhibitors of formula (I), wherein A is (a), (b) or (c), are claimed as well as pharmaceutically acceptable salts and formulations thereof. These compounds are effective in inhibiting testosterone 5 alpha -reductase(s) and are thus useful in the treatment of a number of hyperandrogenic conditions including benign prostatic hypertrophy, acne, seborrhea, female hirsutism, and male and female pattern baldness (alopecia).
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
MERCK 
&
 CO INC
</APPLICANT-NAME>
<APPLICANT-NAME>
MERCK 
&
 CO., INC.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BERGMAN JEFFREY P
</INVENTOR-NAME>
<INVENTOR-NAME>
TOLMAN RICHARD L
</INVENTOR-NAME>
<INVENTOR-NAME>
WITZEL BRUCE E
</INVENTOR-NAME>
<INVENTOR-NAME>
BERGMAN, JEFFREY, P.
</INVENTOR-NAME>
<INVENTOR-NAME>
TOLMAN, RICHARD, L.
</INVENTOR-NAME>
<INVENTOR-NAME>
WITZEL, BRUCE, E.
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
The present invention is directed to novel amino substituted
4-azasteroidal 5α-reductase inhibitors.The art reveals that certain undesirable physiological
manifestations, such as acne vulgaris, seborrhea, female hirsutism, male
pattern baldness and benign prostatic hypertrophy, are the result of
hyperandrogenic stimulation caused by an excessive accumulation of
testosterone or similar androgenic hormones in the metabolic system.
Early attempts to provide a chemotherapeutic agent to counter the
undesirable results of hyperandrogenicity resulted in the discovery of
several steroidal antiandrogens having undesirable hormonal activities
of their own. The estrogens, for example, not only counteract the effect
of the androgens but have a feminizing effect as well. Non-steroidal
antiandrogens have also been developed, for example, 4'-nitro-3'-trifluoromethyl-isobutyranilide.
See Neri, et al., Endo., Vol. 91, No. 2
(1972). However, these products, though devoid of hormonal effect,
are peripherally active, competing with the natural androgens for
receptor sites, and hence have a tendency to feminize a male host or the
male fetus of a female host.It is now known in the art that the principal mediator of
androgenic activity in some target organs is 5α-dihydrotestosterone, and
that it is formed locally in the target organ by the action of testosterone-5α-reductase.
It is also known that inhibitors of testosterone-5α-reductase
will serve to prevent or lessen symptoms of hyperandrogenic
stimulation. A number of 4-azasteroid compounds are known in the art
as 5α-reductase inhibitors. For example, See U.S. Patent Nos.
2,227,876, 3,239,417, 3,264,301 and 3,285,918; French Patent No.
1,465,544; Doorenbos and Solomons, J. Pharm. Sci. 62, 4, pp. 638-640
(1973); Doorenbos and Brown, J. Pharm. Sci., 60, 8, pp. 1234-1235 
(1971); and Doorenbos and Kim, J. Pharm. Sci. 63, 4, pp. 620-622
(1974).In addition, U.S. Patent Nos. 4,377,584, 4,220,775,
4,859,681, 4,760,071 and the articles J. Med. Chem. 27, p. 1690-1701
(1984) and J. Med. Chem. 29, 2998-2315 (19X6) of Rasmusson, et al.,
U.S. Patent 4,845,104 to Carlin, et al., and U.S. Patent 4,732,897 to
Cainelli, et al. describe 4-aza-17β-substituted-5α-androstan-3-ones
which are said to be useful in the treatment of DHT-related hyperandrogenic
conditions.However, despite the suggestion in the prior art that
hyperandrogenic diseases are the result of a single 5α-reductase, there
are reports regarding the presence of other 5α-reductase isozymes in
both rats and humans. For example, in
</DESCRIPTION>
<CLAIMS>
A compound of the formula:


and the pharmaceutically acceptable salts thereof, wherein:

A is:


wherein
R
1
 is:

H,
methyl or ethyl;
R
2
 is: 

H, or
C
1-20
 alkyl;
R
3
 is:

H,
aminoC
1
-C
4
alkyl,
mono C
1
-C
4
alkylaminoC
1
-C
4
alkyl,
di C
1
-C
4
alkylaminoC
1
-C
4
alkyl,
mono C
1
-C
4
 alkylaminoaryl,
di C
1
-C
4
 alkylaminoaryl,
C
1-20
 alkyl,
C
6-14
 aryl,
heteroaryl which is a mono or polycyclic system composed of 5-
or 6-membered aromatic rings consisting of 1,2, 3 or 4

heteroatoms chosen from N, O, or S and either unsubstituted or
substituted with R or independently with hydroxyl, C
1-
-
20
alkyloxy,
C
1-20
alkyl, benzoyl, carboamide, acetamide,
halogens, C
2-20
alkenyl, cyano, nitro, or haloalkyl directly
bonded to the aromatic carbon atoms(s);
C
6-14
 arylC
1-20
alkyl,
heteroarylC
1-20
alkyl,
C
1-20
alkylthioC
1-20
alkyl,
C
1-20
alkylsulfinylC
1-20
alkyl,
C
1-20
alkylsulfonylC
1-20
alkyl,
C
0-10
alkylC
6-14
arylthioC
1-20
alkyl,
C
0-10
alkylC
6-14
arylsulfinylC
1-20
alkyl,
C
0-10
alkylC
6-14
arylsulfonylC
1-20
alkyl,
C
1-20
alkyloxycarbonylC
1-20
alkyl,
carboxylC
1-20
alkyl,
carboC
1-20
alkyloxyC
1-20
alkyl,
C
1-20
alkylcarbonylC
1-20
alkyl,
C
3-20
cycloalkyl,
C
3-20
cycloalkenyl,
C
3-20
cycloalkylC
1-20
alkyl,
C
6-14
 arylC
1-20
alkyloxycarbonylC
1-20
alkyl,
heteroarylC
1-20
alkyloxycarbonylC
1-20
alkyl, 
haloC
1-20
alkyl,
hydroxylC
1-20
alkyl,
iminodibenzylC
1-20
alkylC
6-14
aryl,
halohydroxylC 
1-20
alkyl,
thiosulfatoC
1-20
alkyl,
C
6-14
 arylC
1-20
alkyloxyC
1-20
alkyl,
C
1-20
alkyloxyC
1-20
alkyl,
C
6-14
 arylcarbonylC
6-14
arylC
1-20
alkyl,
diarylC
1-20
alkyl of the formula:


m equals 0-19;
triarylC
1-20
alkyl of the formula:


n equals 1-19;
C
2-20
 alkenyl,
C
2-20
 alkenylC
1-20
alkyl,
C
6-14
aryloxyC
6-14
aryl,
heteroarylC
2-20
alkenyl,
C
6-14
 arylC
2-20
alkenyl,
C
2-20
alkynylC
1-20
alkyl,
C
6-14
arylcarboamideC
6-14
arylC
1-20
alkyl,
phosphonoC
1-20
alkyl,
C
6-14
 arylC
2-20
alkynylC
1-20
alkyl, or 
heteroarylC
2-20
alkynylC
1-20
alkyl;
R
4
 is:

H,
C
1-20
 alkyl,
C
6
 aryl wherein aryl is a monocyclic system composed of 6-membered
aromatic rings either unsubstituted or substituted with

R wherein R is H, C
1-6
 alkyl, arylC
1-20
alkyl with the alkyl
groups unsubstituted or substituted with hydroxyl, C
1-8
alkyloxy,
carboxy C
0-10
alkyl, or halogen or aryl directly substituted
independently with amino, mono C
1
-C
4
 alkylamino, di C
1
-C
4

alkylamino, mono C
1
-C
4
 alkylaminoaryl, di C
1
-C
4

alkylaminoaryl, hydroxyl, haloC
1-20
alkyl, carboxamido,
benzoyl, C
1-20
alkyloxy, C
1-20
alkyl, C
2-20
alkenyl, cyano, nitro.
acetamide or halogen; or

heteroaryl as defined above;
R
7
 or R
8
 are:

H,
CH
3
,
C
2
H
5
,
carboxamido,
C
1-6
 alkylthio,
C
1
-C
6
 alkylsulfinyl,
C
1
-C
6
 alkylsulfonyl,
OCH
3
,
NH
2
,
CH
3
NH,
(CH
3
)
2
N,
OH, 
NO
2
,
CN,
F,
acetamido,
Cl,
OC
2
H
5
,
CF
3
,
isopropyl, or
isobutyl;
W is:


or


wherein unless otherwise specified aryl denotes a mono- or polycyclic
system composed of 6-membered aromatic rings either unsubstituted or

substituted with either R, wherein R represents hydrogen, C
1-6
alkyl or
arylC
1-20
alkyl, wherein alkyl is unsubstituted or substituted with
C
1-8
alkyloxy, carboxyC
0-10
alkyl, hydroxy or halogen; or substituted with
any of hydroxyl, C
1-10
alkyl, C
2-20
alkenyl, C
1-20
alkyloxy, haloC
1-20
alkyl,
benzoyl, cyano, nitro, carboxamide, acetamido or halogen;

and the dashed indicate a double bond is optionally present.
A compound of the formula: 


and the pharmaceutically acceptable salts thereof, wherein:

A is:


wherein
R
1
 is:

H,
methyl, or ethyl;
R
2
 is:

H, or
C
1-20
alkyl;
R
3
 is:

H,
C
1-20
alkyl is a straight or branched chain alkane of up to 20
carbon atoms;
C
6-14
 aryl wherein aryl is a mono or polycyclic system
composed of 6-membered aromatic rings either unsubstituted or

substituted with R wherein R is H, C
1-6
 alkyl, arylC
1-20
alkyl
with the alkyl groups unsubstituted or substituted with hydroxyl,

C
1-8
alkyloxy, carboxy C
0-10
alkyl, or halogen or aryl directly
substituted independently with amino, mono C
1
-C
4
 alkylamino, di
C
1
-C
4
 alkylamino, mono C
1
-C
4
 alkylaminoaryl, di C
1
-C
4

alkylaminoaryl, hydroxyl, haloC
1-20
alkyl, carboxamido,
benzoyl, C
1-20
alkyloxy, C
1-20
alkyl, C
2-20
alkenyl, cyano, nitro,
acetamide or halogen;
heteroaryl as defined in claim 1;
C
6-14
 arylC
1-20
alkyl of the formula:


wherein the aromatic ring is optionally and independently
substituted with R
7
 and R
8
 wherein R
7
 and R
8
 are
H, 
CH
3
,
C
2
H
5
,
carboxamido,
C
1
-C
6
 alkylthio,
C
1
-C
6
 alkylsulfinyl,
C
1
-C
6
 alkylsulfonyl,
OCH
3
,
NH
2
,
CH
3
NH,
(CH
3
)
2
N,
OH,
NO
2
,
CN,
F,
acetamido,
Cl,
OC
2
H
5
,
CF
3
,
isopropyl, or
isobutyl; p equals 1-20 and the C
1-20
alkyl portion is optionally
substituted with R
5
;
HeteroarylC
1-20
alkyl of the formula:


or


wherein X equals O, S, or NR; and p equals 1-20;
C
1-20
alkylsulfonylC
1-20
alkyl, 
C
1-20
alkylthioC
1-20
alkyl,
C
1-20
alkylsulfinylC
1-20
alkyl of the formula:

-(CH
2
)
q
S(O)
r
-R
9

wherein R
9
 is
C
0-10
alkylC
6-14
aryl, wherein aryl denotes a mono- or polycyclic system
composed of 6-membered aromatic rings either unsubstituted or

substituted with either R, wherein R represents hydrogen, C
1-6
alkyl or
arylC
1-20
alkyl, wherein alkyl is unsubstituted or substituted with
C
1-8
alkyloxy, carboxyC
0-10
alkyl, hydroxy or halogen; or substituted with
any of hydroxyl, C
1-10
alkyl, C
2-20
alkenyl, C
1-20
alkyloxy, haloC
1-20
alkyl,
benzoyl, cyano, nitro, carboxamide, acetamido or halogen;
CH
3
,
C
2
H
5
,
C
3
H
7
,
C
4
H
9
,
isopropyl,
isobutyl,
sec-butyl,
t-butyl,
isopentyl,
neopentyl, or
isohexyl; q equals 1-15 and r=0-2;
C
1-20
alkyloxycarbonylC
1-20
alkyl of the formula:


wherein R
10

is:
CH
3
,
C
2
H
5
,
C
3
H
7
,
C
4
H
9
, or
C
5
H
11
; and p equals 1-20; 
CarboxylC
1-20
alkyl of the formula:


p = 1-20;
C
1-20
alkylcarbonylC
1-20
alkyl of the formula 


p equals 1-20;
m equals 0-19;
C
3-20
cycloalkylC
1-20
alkyl of the formula:
-(CH
2
)
p
-(cycloalkyl) wherein the cycloalkyl protion is a
monocyclic, bicyclic, or polycyclic hydrocarbon of up to 20

carbon atoms wherein the rings are optionally substituted with
R
1
; and p = 1-20;
ArylC
1-20
alkyloxycarbonylC
1-20
alkyl of the formula:


wherein p equals 1-20;
HeteroarylC
1-20
alkyloxycarbonylC
1-20
alkyl of the formula:


wherein Heteroaryl is as defined in claim 1 and p equals 1-20;
haloC
1-20
alkyl of the formula:

-(CH
2
)
n
-CH
2
X

wherein
X equals Br, Cl, F or I; n is 1-19;
hydroxylC
1-20
alkyl of the formula:

-(CH
2
)
n
CH
2
OH;

n is 1-19;
halohydroxylC
1-20
alkyl of the formula: 


wherein

s=1-18
t=0-18
s+t=0-18 and
X equals Br, Cl, F or I;
ThiosulfatoC
1-20
alkyl of the formula:

-(CH
2
)
n
CH
2
SSO
3
Na;

n is 1-19;
phosphonoC
1-20
alkyl of the formula:

-(CH
2
)
p
P(O)(OR)
2

wherein R is lower alkyl and p equals 1-20;
ArylC
1-20
alkyloxyC
1-20
alkyl of the formula:


p equals 1-20;
ArylcarbonylarylC
1-20
alkyl of the formula:


p equals 1-20;
DiarylC
1-20
alkyl of the formula:


m equals 0-19; 
TriarylC
1-20
alkyl of the formula:


n equals 1-19;
Aryl C
2-20
alkenyl of the formula:

t = 0-18
u = 0-18
t+u = 0-18;
R
4
 is

H,
C
1-20
alkyl,
C
6
 aryl wherein aryl is a monocyclic system composed of 6-membered
aromatic rings either unsubstituted or substituted with

R wherein R is H, C
1-6
 alkyl, arylC
1-20
alkyl with the alkyl
groups unsubstituted or substituted with hydroxyl, C
1-8
alkyloxy,
carboxy C
0-10
alkyl, or halogen or aryl directly substituted
independently with amino, mono C
1
-C
4
 alkylamino, di C
1
-C
4

alkylamino, mono C
1
-C
4
 alkylaminoaryl, di C
1
-C
4

alkylaminoaryl, hydroxyl, haloC
1-20
alkyl, carboxamido
benzoyl, C
1-20
alkyloxy, C
1-20
alkyl, C
2-20
alkenyl, cyano, nitro,
acetamide or halogen; or 
heteroaryl as defined in claim 1;
R
5
 is

H, or
C
1-12
alkyl;
W is:


or


and the dashes indicate a double bond is optionally present.
A compound according to Claim 1 or Claim 2 and the
pharmaceutically acceptable salts thereof, wherein,


A is:

R
1
 is:

H,
methyl or ethyl:
R
2
 is:

H, or
C
1-12
 alkyl;
R
3
 is:

H,
C
1-20
 alkyl,
C
6-14
 aryl,
heteroaryl as defined in claim 1;
C
6-14
 arylC
1-20
alkyl,
heteroarylC
1-20
alkyl, wherein the heteroaryl moiety is as
defined in claim 1;
C
1-20
alkylthioC
1-20
alkyl,
C
1-20
alkyloxycarbonylC
1-20
alkyl,
carboxylC
1-20
alkyl,
C
1-20
 alkylcarbonylC
1-20
alkyl,
C
3-20
cycloalkyl,
C
3-20
cycloalkylC
1-20
alkyl,
C
6-14
 arylC
1-20
alkyloxycarbonylC
1-20
alkyl,
heteroarylC
1-20
alkyloxycarbonylC
1-20
alkyl,
haloC
1-20
alkyl,
hydroxyC
1-20
alkyl,
halohydroxyC
1-20
alkyl,
thiosulfatoC
1-20
alkyl,
C
6-14
 arylcarbonylC
6-14
arylC
1-20
alkyl,
C
6-14
 arylC
1-20
alkyloxyC
1-20
alkyl,
C
1-20
cycloalkylC
1-20
alkyl,
diarylC
1-20
alkyl of the formula:


m equals 0-19;
triarylC
1-20
alkyl of the formula: 


n equals 1-19; or
C
2-20
 alkenyl;
R
4
 is:

H,
C
1-20
 alkyl,
C
6-14
 aryl wherein aryl is a monocyclic system composed
of 6-membered aromatic rings either unsubstituted or

substituted with R wherein R is H, C
1-6
 alkyl, arylC
1-
-
20
alkyl
with the alkyl groups unsubstituted or substituted

with hydroxyl, C
1-8
alkyloxy, carboxy C
0-10
alkyl, or
halogen or aryl directly substituted independently with

amino, mono C
1
-C
4
 alkylamino, di C
1
-C
4
 alkylamino,
mono C
1
-C
4
 alkylaminoaryl, di C
1
-C
4
 alkylaminoaryl,
hydroxyl, haloC
1-20
alkyl, carboxamido, benzoyl, C
1-
-
20
alkyloxy,
C
1-20
alkyl, C
2-20
alkenyl, cyano, nitro,
acetamide or halogen; or
heteroaryl as defined in claim 1.
A compound according to Claim 3 and the
phar
maceutically acceptable salts thereof wherein:

R
1
 is:

H,
methyl, or
ethyl;
R
2
 is:

H,
methyl,
ethyl, linear or branched:
propyl,
butyl,
pentyl,
hexyl, or heptyl;
R
3
 is:

t-butyl,
2,2-diphenylethyl,
3-thienyl,
2-thienyl,
11-(isopropylthio)undecyl,
7-(carbomethoxy)heptyl,
1-(1-(4-isobutylphenyl-)ethyl,
7-(carboxy)heptyl,
acetylmethyl,
1-adamantylmethyl,
2-thienylmethyl,
2-(carbobenzyloxy)ethyl,
3,4-dimethoxyphenyl,
phenyl,
5-bromopentyl,
phenylthiomethyl,
t-butylthiomethyl,
3-methyl-2-thienyl,
5-methyl-2-thienyl,
11-hydroxyundecyl,
1-(4-nitrophenyl)ethyl, 
isopropylthiomethyl,
5-(thiosulfato)pentyl,
benzyloxymethyl,
carbomethoxymethyl,
diphenylmethyl,
triphenylmethyl,
2-furyl,
4-isopropylphenyl,
cyclohexylmethyl,
4-methylcyclohexyl,
3-(3-indolyl)propyl,
3-Indolylmethyl,
4-isobutylphenyl,
4-nitrophenyl,
3-nitrophenyl,
3-acetamidomethyl,
4-ethoxyphenyl,
hexadecyl,
stearyl,
3,5-Bis(trifluoromethyl)benzyl,
3-cyanophenyl,
heptafluoropropyl,
4-benzoylphenyl,
5-benztriazolyl,
3,5-difourophenyl,
bis(4-isopropylphenyl)methyl,
2-hydroxyphenyl,
phenylvinyl,
2-hydroxy-3,3,3-trichloropropyl,
methyl,
allyl,
n-propyl,
n-octyl,
isopropyl, 
(isopropylthio)methyl,
isobutyl,
ethyl,
2,2,2-triphenylethyl,
benzyl,
octadecyl,
2(ethyl)phenyl,
3(chloro)phenyl,
4(methyl)phenyl,
2,3(dichloro)phenyl,
2,6(dichloro)phenyl,
4(fluoro)phenyl,
3(methoxy)phenyl,
3-(acetamido)phenyl,
3-(Iminodibenz-5-ylmethyl)phenyl,
3-trifluoromethylphenyl,
2(ethoxy)phenyl,
formyl,
2-napthyl, or
2-thiazolyl;
R
4
 is:

H,
methyl,
ethyl, linear or branched:
propyl,
butyl,
C
6-14
 aryl wherein aryl is a monocyclic system composed
of 6-membered aromatic rings either unsubstituted or

substituted with R wherein R is H, C
1-6
 alkyl, arylC
1-
-
20
alkyl
with the alkyl groups unsubstituted or substituted

with hydroxyl, C
1-8
alkyloxy, carboxy C
0-10
alkyl, or
halogen or aryl directly substituted independently with 

amino, mono C
1
-C
4
 alkylamino, di C
1
-C
4
 alkylamino,
mono C
1
-C
4
 alkylaminoaryl, di C
1
-C
4
 alkylaminoaryl,
hydroxyl, haloC
1-20
alkyl, carboxamido, benzoyl, C
1-
-
20
alkyloxy,
C
1-20
alkyl, C
2-20
alkenyl, cyano, nitro,
acetamide or halogen; or
heteroaryl as defined in claim 1;
W is:

The compound according to Claim 4 and the
pharmaceutically acceptable salts thereof, wherein the compound

is selected from :

4-Methyl-20(trimethylacetamido)5α-4-aza-pregnan-3-one,
4-Methyl-17β(trimethylacetamidomethyl)-4-aza-5α-androstan-3-one,
4-Methyl-17β(2-thiophenesulfonamidomethyl)-4-aza-5α-androstan-3-one,
17β(Isopropylthiododecanoylamidomethyl)-4-aza-5α-androstan-3-one,
4-Methyl-17β(thiophenecarboxamidomethyl)-4-aza-5α-androstan-3-one,
17β(Carbomethoxyoctanoylamidomethyl)-4-methyl-4-aza-5α-androstan-3-one, 
17β(2-(4-isobutylphenyl)propionamidomethyl)-4-Methyl-4-aza-5α-androstan-3-one,
17β(8-Carboxyoctanoylamidomethyl)-4-methyl-4-aza-5α-androstan-3-one,
17β(Acetoacetamidomethyl)-4-methyl-4-aza-5α-androstan-3-one,
4-Methyl-17β(2-thiopheneacetamidomethyl)-4-aza-5α-androstan-3-one,
17β(3-(carbobenzyloxy)propioamidomethyl)-4-Methyl-4-aza-5α-androstan-3-one,
17β(3,4-dimethoxyphenylacetamidomethyl)-4-Methyl-4-aza-5α-androst-3-one,
17β(Benzenesulfonamidomethyl)-4-methyl-4-aza-5α-androstan-3-one,
17β(6-Bromohexanoylamidomethyl)-4-methyl-4-aza-5α-androstan-3-one,
17β(12-Hydroxydodecanoylamidomethyl)-4-methyl-4-aza-5α-androstan-3-one,
4-Methyl-17β(2-(4-nitrophenyl)propionamidomethyl)-4-aza-5α-androstan-3-one,
17β(Isopropylthioacetamidomethyl)-4-methyl-4-aza-5α-androstan-3-one,
4-Methyl-17β(6-(thiosulfato)hexanoylamidomethyl)-4-aza-5α-androstan-3-one, 
17β(Benzyloxyacetamidomethyl)-4-methyl-4-aza-5α-androstan-3-one,
17β(Carbomethoxyacetamidomethyl)-4-methyl-4-aza-5α-androstan-3-one,
17β(Diphenylacetamidomethyl)-4-methyl-4-aza-5α-androstan-3-one,
4-Methyl-17β(3,3,3-triphenylpropionamidomethyl)-4-aza-5α-androstan-3-one,
17β(2-Furylacetamidomethyl)-4-methyl-4-aza-5α-androstan-3-one,
17β(4-Isopropylphenylacteamidomethyl)-4-methyl-4-aza-5α-androstan-3-one,
17β(Cyclohexylacetamidomethyl)-4-methyl-4-aza-5α-androstan-3-one,
17β(3-indolylacetamidomethyl)-4-methyl-4-aza-5α-androstan-3-one,
4-Methyl-17β(4-Methylcyclohexanecarboxamidomethyl)-4-aza5α-androstan-3-one,
17β(4-(3-Indolyl)-butyramidomethyl)-4-methyl-4-aza-5α-androstan-3-one,
17β(4-Isobutylbenazmidomethyl)-4-methyl-4-aza-5α-androstan-3-one, 
17β(Acetoxyacetamidomethyl)-4-methyl-4-aza-5α-androstan-3-one,
17β(6-Bromohexanoylamidomethyl)-4-Methyl-4-aza-5α-androstan-3-one,
20-((3-Acetamido)benzamido)-4-Methyl-4-aza-5α-pregnan-3-one,
17β(4-Ethoxybenzamidomethyl)-4-methyl-4-aza-5α-androstan-3-one,
17β(Iminodibenzyl-5-carboxamidomethyl)-4-methyl-4-aza-5α-androstan-3-one,
4-Methyl-20-(stearoylamido)-4-aza-5α-pregnan-3-one,
4-Methyl-17β-(3,5-bis-(trifluoromethyl)benzamidomethyl)4-aza-5α-androstan-3-one,
17β(3-Cyanobenzamidomethyl)-4-methyl-4-aza-5α-androstan-3-one,
17β(Benztriazole-5-carboxamidomethyl)-4-methyl-4-aza-5α-androstan-3-one,
20-(3,5-diflurobenzamido)-4-methyl-4-aza-5α-pregnan-3-one,
17β(Bis-(4-Isopropyl)phenyl)acetamidomethyl-4-methyl-aza-5α-androstan-3-one,
17β(Cinnamoylamidomethyl)-4-methyl-4-aza-5α-androstan-3-one, 
17β((3-Hydroxy-4,4,4-trichlorobutyramido)methyl)-4-methyl-4-aza-5α-androstan-3-one,
17β-(2,6-Dichlorobenzamidomethyl)-5-α-4-methyl-4-azaandrosatan-3-one,
17β-(3-Nitrobenzoylamidomethyl)-5-α-4-methyl-4-azaandrostan-3-one,
17β-(4-Nitrobenzoylamidomethyl)-5-α-4-methyl-4-azaandrostan-3-one,
17β-(3,3-Diphenylpropionamidomethyl)-5-α-4-methyl-4-azaandrostan-3-one,
17β-((3-(Iminodibenz-5-ylmethyl)benzoyl)aminomethyl)-4-methyl-5-α-4-azaandrostan-3-one,
17β-(3-Hydroxy-4,4,4,-trichlorobutyroylamidomethyl))-5-α-4-methyl-4-azaandrostan-3-one,
17β-Formamidomethyl-5-α-4-methyl-4-azaandrostan-3-one,
4-Methyl-17β-(3,3,3-triphenylpropionamidomethyl)-5-α-4-azaandrostan-3-one,
20-((Isopropylthio)acetamido)-4-methyl-5-α-4-azapregnan-3-one,
20-((Isopropylthio)acetamido)-5-α-4-azapregnan-3-one,
4-Methyl-17β-(phenylthio)acetamidomethyl)-5-α-4-azaandrostan-3-one,
17β-((t-Butylthio)acetamidomethyl)-5-α-4-methyl-4-azaandrostan-3-one,
17β-(3-Methyl-2-thenoylaminomethyl)-4-methyl-5-α-4-azaandrostan-3-one, 
17β-(5-Methyl-2-thenoylaminomethyl)-4-methyl-5-α-4-azaandrostan-3-one,
4-Methyl-17β-(3-(trifluoromethyl)-benzamidomethyl)-5-α-4-azaandrostan-3-one,
or
17β-Benzamidomethyl-4-methyl-5-α-4-azaandrostan-3-one.
The compound according to Claim 4 and the
pharmaceutically acceptable salts thereof, wherein the compound is

selected from:

4-Methyl-20(trimethylacetamido)5α-4-aza-pregn-1-en-3-one,
4-Methyl-17β(trimethylacetamidomethyl)-4-aza-5α-androst-1-en-3-one,
4-Methyl-17β(2-thiophenesulfonamidomethyl)-4-aza-5α-androst-1-en-3-one,
17β(isopropylthiododecanoylamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
4-Methyl-17β(thiophenecarboxamidomethyl)-4-aza-5α-androst-1-en-3-one,
17β(-8-(Carbomethoxy)octanoylamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
17β(2-(4-Isobutylphenyl)propionamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
17β(8-Carboxyoctanoylamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one, 
17β(Acetoacetamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
17β(1-Adamantylacetamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
4-Methyl-17β(2-thiopheneacetamidomethyl)-4-aza-5α-androst-1-en-3-one,
17β(3-(Carbobenzyloxy)propionamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
17β(3,4-Dimethoxyphenylacetamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
17β(Benzenesulfonamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
17β(6-Bromohexanoylamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
17β(12-Hydroxydodecanoylamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
4-Methyl-17β(2-(4-nitrophenyl)propionamidomethyl)-4-aza-5α-androst-1-en-3-one,
17β(Isopropylthioacetamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
4-Methyl-17β(6-(thiosulfato)hexanoylamidomethyl)-4-aza-5α-androst-1-en-3-one, 
17β(Benzyloxyacetamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
17β(Carbomethoxyacetamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
17β(Diphenylacetamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
4-Methyl-17β(3,3,3-triphenylpropionamidomethyl)-4-aza-5α-androst-1-en-3-one,
17β(2-Furylacetamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
17β(4-Isopropylphenylacetamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
17β(Cyclohexylacetamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
17β(3-Indolylacetamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
4-Methyl-17β(4-methylcyclohexanecarboxamidomethyl)-4-aza-5α-androst-1-en-3-one,
17β(4-(3-Indolyl)-butyramidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
17β(4-Isobutylbenzamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
17β(Acetoxyacetamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one, 
17β(6-Bromohexanoylamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
20-((3-Acetamido)benzamido)-4-methyl-4-aza-5α-pregn-1-en-3-one,
17β(4-Ethoxybenzamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
17β-(Iminodibenzyl-5-carboxamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
4-Methyl-20-(stearoylamido)-4-aza-5α-pregn-1-en-3-one,
4-Methyl-17β-(3,5-Bis-(trifluoromethyl)benzamidomethyl)-4-aza-5α-androst-1-en-3-one,
17β-(3-Cyanobenzamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
17β-(Benztriazol-5-carboxamidomethyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
20-(3,5-Difluorobenzamido)-4-methyl-4-aza-5α-pregn-1-en-3-one,
17β-(Bis-(4-Isopropyl)phenyl)acetamidomethyl-4-methyl-aza-5α-androst-1-en-one,
17β-(Cinnamoylamidomethyl)-4-Methyl-4-aza-5α-androst-1-en-3-one, 
17β-((3-Hydroxy-4,4,4,-trichlorobutyramido)methyl)-4-methyl-4-aza-5α-androst-1-en-3-one,
17β-(2,6-Dichlorobenzamidomethyl)-5-α-4-methyl-4-azaandrosatan-1-en-3-one,
17β-(3-Nitrobenzoylamidomethyl)-5-α-4-methyl-4-azaandrostan-1-en-3-one,
17β-(4-Nitrobenzoylamidomethyl)-5-α-4-methyl-4-azaandrostan-1-en-3-one,
17β-(3,3-Diphenylpropionamidomethyl)-5-α-4-methyl-4-azaandrostan-1-en-3-one,
17β-((3-(Iminodibenz-5-ylmethyl)benzoyl)aminomethyl)-4-methyl-5-α-4-azaandrostan-1-en-3-one,
17β-(3-Hydroxy-4,4,4,-trichlorobutyroylamidomethyl))-5-α-4-methyl-4-azaandrostan-1-en-3-one,
17β-Formamidomethyl-5-α-4-methyl-4-azaandrostan-1-en-3-one,
4-Methyl-17β-(3,3,3,-triphenylpropionamidomethyl)-5-α-4-azaandrostan-1-en-3-one,
20-((Isopropylthio)acetamido)-4-methyl-5-α-4-azapregnan-1-en-3-one,
20-((Isopropylthio)acetamido)-5-α-4-azapregnan-1-en-3-one,
4-Methyl-17β-((phenylthio)acetamidomethyl)-5-α-4-azaandrostan-1-en-3-one,
17β-((t-Butylthio)acetamidomethyl)-5-α-4-methyl-4-azaandrostan-1-en-3-one, 
17β-(3-Methyl-2-thenoylaminomethyl)-4-methyl-5-α-4-azaandrostan-1-en-3-one,
17β(5-Methyl-2-thenoylaminomethyl)-4-methyl-5-α-4-azaandrostan-1-en-3-one,
4-Methyl-17β-(3-(trifluoromethyl)-benzamidomethyl)-5-α-4-azaandrostan-1-en-3-one,
17β-(2,6-Dichlorobenzamidomethyl)-5-α-4-methyl-4-azaandrosatan-1-en-3-one,
17β-(3-Nitrobenzoylamidomethyl)-5-α-4-methyl-4-azamidrostan-1-en-3-one,
17β(4-Nitrobenzoylamidomethyl)-5-α-4-methyl-4-azaandrostan-1-en-3-one,
17β-(3,3-Diphenylpropionamidomethyl)-5-α-4-methyl-4-azaandrostan-1-en-3-one,
17β-((3-(Iminodibenz-5-ylmethyl)benzoyl)aminomethyl)-4-methyl-5-α-4-azaandrostan-1-en-3-one,
17β-(3-Hydroxy-4,4,4,-trichlorobutyroylamidomethyl))-5-α-4-methyl-4-azamidrostan-1-en-3-one,
17β-Formamidomethyl-5-α-4-methyl-4-azaandrostan-1-en-3-one,
4-Methyl-17β-(3,3,3-triphenylpropionamidomethyl)-5-α-4-azaandrostan
1-en-3-one,
20-((Isopropylthio)acetamido)-4-methyl-5-α-4-azapregnan-1-en-3-one,
20-(Isopropylthio)acetamido)-5-α-4-azapregnan-1-en-3-one,
4-Methyl-17β-((phenylthio)acetamidomethyl)-5-α-4-azaandrostan-1-en-3-one, 
17-((t-Butylthio)acetamidomethyl)-5-α-4-methyl-4-azaandrostan-1-en-3-one,
17β-(3-Methyl-2-thenoylaminomethyl)-4-methyl-5-α-4-azaandrostan-1-en-3-one,
17β-(5-Methyl-2-thenoylaminomethyl)-4-methyl-5-α-4-azaandrostan-1-en-3-one,
4-Methyl-17β-(3-(trifluoromethyl)-benzamidomethyl)-5-α-4-azaandrostan-1-en-3-one,
or
17β-Benzamidomethyl-4-methyl-5-α-4-azaandrostan-1-en-3-one, 
4-Methyl-20-(palmitoylaminomethyl)-4-aza-5α-1-pregnen-3-one,
20(Heptafluorobutyramidomethyl)-4-methyl-4-aza-5α-1-pregnen-3-one,
or
4-Methyl-20(Salicylamidomethyl)-4-aza-5α-1-pregnen-3-one.
A pharmaceutical composition comprising a
therapeutically effective amount of a compound of Claim 1 in a

pharmaceutically acceptable carrier therefor.
The use of the compound defined in Claim 1
for the manufacture of a medicament for treating benign

prostatic hyperplasia, acne, female hirsutism, male
pattern baldness, androgenic alopecia, prostatitis,

and/or preventing prostatic carcinoma.
The use as claimed in Claim 8 wherein
said compound is an inhibitor of 5α-reductase 1.
The use as claimed in Claim 8 wherein
said compound is an inhibitor of 5α-reductase 2.
The use as claimed in Claim 8 wherein
said compound is a dual inhibitor of both 5α-reductase 1

and 2.
</CLAIMS>
</TEXT>
</DOC>
